HilleVax, Inc. (HLVX)

NASDAQ: HLVX · Real-Time Price · USD
1.790
-0.030 (-1.65%)
At close: Nov 20, 2024, 4:00 PM
1.780
-0.010 (-0.56%)
Pre-market: Nov 21, 2024, 4:06 AM EST
-1.65%
Market Cap 86.34M
Revenue (ttm) n/a
Net Income (ttm) -150.28M
Shares Out 48.23M
EPS (ttm) -3.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,231
Open 1.810
Previous Close 1.820
Day's Range 1.790 - 1.810
52-Week Range 1.550 - 20.220
Beta 0.77
Analysts Hold
Price Target 2.33 (+30.17%)
Earnings Date Nov 7, 2024

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 90
Stock Exchange NASDAQ
Ticker Symbol HLVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for HLVX stock is "Hold." The 12-month stock price forecast is $2.33, which is an increase of 30.17% from the latest price.

Price Target
$2.33
(30.17% upside)
Analyst Consensus: Hold
Stock Forecasts

News

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine can...

3 months ago - GlobeNewsWire

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

Stakeholders Of HilleVax Inc Are Urged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. (“HilleVax” or “the C...

4 months ago - GlobeNewsWire

HLVX Investors Are Invited By The Schall Law Firm To Join Its Investigation Into Alleged Securities Fraud At HilleVax Inc.

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

The Schall Law Firm Invites HLVX Investors To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

HLVX Investors Are Welcomed By The Schall Law Firm To Join Its Inquiry Into Suspected Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

The Schall Law Firm Encourages HLVX Stakeholders To Join Its Probe Into Suspected Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Into Alleged Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

Stakeholders Of HLVX Are Urged To Join The Schall Law Firm's Investigation Of Securities Fraud At HilleVax Inc

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

HLVX Stakeholders Are Encouraged To Participate In The Securities Fraud Investigation Of HilleVax Inc Led By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...

4 months ago - Accesswire

HLVX Stakeholders Are Invited To Join The HilleVax Inc Securities Fraud Probe Conducted By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("H...

4 months ago - Accesswire

Gold Falls Over 1%; HilleVax Shares Plunge

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday.

4 months ago - Benzinga

Investors In HLVX Can Participate In The Securities Fraud Investigation Of HilleVax Inc With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("H...

4 months ago - Accesswire

HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm.

4 months ago - Business Wire

Vaccine Developer HilleVax Stock Nosedives On Monday - Here's Why

Shares of vaccine-developer HilleVax Inc HLVX are down on Monday on a session volume of over 7 million as per data from Benzinga Pro.

4 months ago - Benzinga

HilleVax shares plummet after norovirus vaccine fails in mid-stage study

Shares of biotech company HilleVax plunged 88.6% to $1.60 in premarket trade on Monday, after its vaccine to prevent gastroenteritis caused by norovirus failed to meet the main goal of a mid-stage tri...

4 months ago - Reuters

HilleVax's stock craters after biotech says it's scrapping a norovirus vaccine for infants after a failed trial

HilleVax Inc.'s stock HLVX, -0.28% cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals. Th...

4 months ago - Market Watch

HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants

4 months ago - GlobeNewsWire

HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation

HilleVax, Inc. top line results from the phase 2/3 NEST-IN1 study, using HIL-214 for the prevention of Norovirus-related gastroenteritis, expected mid-2024. Several other studies have already been ini...

8 months ago - Seeking Alpha